Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30082-8 ◽

2019 ◽

Vol 20 (5) ◽

pp. 686-700 ◽

Cited By ~ 101

Author(s):

Karim Fizazi ◽

NamPhuong Tran ◽

Luis Fein ◽

Nobuaki Matsubara ◽

Alfredo Rodriguez-Antolin ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

High Risk ◽

Abiraterone Acetate ◽

Newly Diagnosed ◽

Phase 3 ◽

Double Blind ◽

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30860-x ◽

2019 ◽

Vol 20 (3) ◽

pp. 408-419 ◽

Cited By ~ 89

Author(s):

Matthew Smith ◽

Chris Parker ◽

Fred Saad ◽

Kurt Miller ◽

Bertrand Tombal ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study

International Journal of Urology ◽

10.1111/iju.13051 ◽

2016 ◽

Vol 23 (5) ◽

pp. 404-411 ◽

Cited By ~ 11

Author(s):

Yinghao Sun ◽

Qing Zou ◽

Zhongquan Sun ◽

Changling Li ◽

Chuanjun Du ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Bridging Study

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2016.69.7748 ◽

2017 ◽

Vol 35 (1) ◽

pp. 124-125 ◽

Cited By ~ 24

Author(s):

Philip W. Kantoff ◽

James L. Gulley ◽

Cesar Pico-Navarro

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Phase Ii ◽

Controlled Study ◽

Double Blind ◽

Castration Resistant ◽

Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial

European Urology ◽

10.1016/j.eururo.2019.07.021 ◽

2019 ◽

Vol 76 (5) ◽

pp. 705-706

Author(s):

Henk van der Poel

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Radium 223

Re: Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

European Urology ◽

10.1016/j.eururo.2010.06.020 ◽

2010 ◽

Vol 58 (3) ◽

pp. 466 ◽

Cited By ~ 1

Author(s):

David S. Finley ◽

Frederic Pouliot ◽

Allan Pantuck

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Randomized Controlled Trial ◽

Survival Analysis ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Overall Survival Analysis ◽

Targeted Immunotherapy

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

European Journal of Cancer ◽

10.1016/s0959-8049(11)71951-7 ◽

2011 ◽

Vol 47 ◽

pp. S483-S484 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

H.I. Scher ◽

A. Molina ◽

C.J. Logothetis ◽

R.J. Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Phase 3 ◽

Castration Resistant

Faculty Opinions recommendation of Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740905744.793589416 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79581-6 ◽

2011 ◽

Vol 2011 ◽

pp. 110-111

Author(s):

C.A. Lawton

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Randomized Controlled Trial ◽

Survival Analysis ◽

Controlled Trial ◽

Randomized Controlled ◽

Castration Resistant ◽

Overall Survival Analysis ◽

Targeted Immunotherapy